ClinicalTrials.gg
CompletedNCT07222098Updated May 6, 2026

A Clinical Study of Calderasib (MK-1084) With Rosuvastatin and Metformin in Healthy People (MK-1084-016)

A Phase 1 interventional study of Rosuvastatin and Metformin in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 19 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
19 Years to 60 Years
Sex
All
01

Study summary

Researchers want to learn about calderasib when given with rosuvastatin and metformin in healthy people. The goal of this study is to compare the amount of rosuvastatin and metformin in a person's body over time when given with and without calderasib

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

- Has (BMI) ≥ 18.0 and ≤ 32.0 kg/m\^2

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has history of cancer ()
  • Positive results for (HIV), surface antigen (HBsAg), or virus (HCV)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Rosuvastatin + metformin

    Participants will receive rosuvastatin plus metformin

    Drug: Rosuvastatin · Drug: Metformin

  • Experimental
    Rosuvastatin + metformin + Calderasib

    Participants will receive rosuvastatin plus metformin plus calderasib

    Drug: Rosuvastatin · Drug: Metformin · Drug: Calderasib

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Rosuvastatin

    Blood samples will be collected at multiple time points to determine the AUC0-inf of rosuvastatin

    Time frame: Day 1: Predose and at designated timepoints up to 120 hours post-dose

  2. Maximum Plasma Concentration (Cmax) of Rosuvastatin

    Blood samples will be collected at multiple time points to determine the Cmax of rosuvastatin

    Time frame: Day 1: Predose and at designated timepoints up to 120 hours post-dose

  3. AUC0-inf of Metformin

    Blood samples will be collected at multiple time points to determine the AUC0-inf of metformin

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

Secondary outcomes

  1. Area Under the Curve From Time 0 to Last Quantifiable Sample (AUC0-last) of Rosuvastatin

    Blood samples will be collected at multiple time points to determine the AUC0-last of rosuvastatin

    Time frame: Day 1: Predose and at designated timepoints up to 120 hours post-dose

  2. Area Under the Curve From Time 0 to 24 Hours (AUC0-24hrs) of Rosuvastatin

    Blood samples will be collected at multiple time points to estimate AUC0-24

    Time frame: Day 1: Predose and at designated timepoints up to 24 hours post-dose

  3. Time to Maximum Plasma Concentration (Tmax) of Rosuvastatin

    Blood samples will be collected at multiple time points to estimate Tmax

    Time frame: Day 1: Predose and at designated timepoints up to 120 hours post-dose

  4. Day 1: Apparent Terminal Half-life (t1/2) of Rosuvastatin

    Blood samples will be collected at multiple time points to estimate t1/2

    Time frame: Day 1: Predose and at designated timepoints up to 120 hours post-dose

  5. Apparent Clearance (CL/F) of Rosuvastatin

    Blood samples will be collected at multiple time points to estimate CL/F

    Time frame: Day 1: Predose and at designated timepoints up to 120 hours post-dose

  6. Apparent Volume of Distribution During Terminal Phase (Vz/F) of Rosuvastatin

    Blood samples will be collected at multiple time points to estimate Vz/F

    Time frame: Day 1: Predose and at designated timepoints up to 120 hours post-dose

  7. AUC0-last of Metformin

    Blood samples will be collected at multiple time points to estimate AUC0-last

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  8. AUC0-24hrs of Metformin

    Blood samples will be collected at multiple time points to estimate AUC0-24

    Time frame: Day 1: Predose and at designated timepoints up to 24 hours post-dose

  9. Cmax of Metformin

    Blood samples will be collected at multiple time points to estimate Cmax

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  10. Tmax of Metformin

    Blood samples will be collected at multiple time points to estimate Tmax

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  11. t1/2 of Metformin

    Blood samples will be collected at multiple time points to estimate t1/2

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  12. CL/F of Metformin

    Blood samples will be collected at multiple time points to estimate CL/F

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  13. Vz/F of Metformin

    Blood samples will be collected at multiple time points to estimate Vz/F

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  14. AUC0-inf of Calderasib

    Blood samples will be collected at multiple time points to estimate AUC0-inf

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  15. AUC0-last of Calderasib

    Blood samples will be collected at multiple time points to estimate AUC0-last

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  16. AUC0-24hrs of Calderasib

    Blood samples will be collected at multiple time points to estimate AUC0-24

    Time frame: Day 1: Predose and at designated timepoints up to 24 hours post-dose

  17. Cmax of Calderasib

    Blood samples will be collected at multiple time points to estimate Cmax

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  18. Plasma Concentration at 24 Hours (C24) of Calderasib

    Blood samples will be collected to estimate C24

    Time frame: 24 hours post-dose

  19. Tmax of Calderasib

    Blood samples will be collected at multiple time points to estimate Tmax

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  20. t1/2 of Calderasib

    Blood samples will be collected at multiple time points to estimate t1/2

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  21. CL/F of Calderasib

    Blood samples will be collected at multiple time points to estimate CL/F

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  22. Vz/F of Calderasib

    Blood samples will be collected at multiple time points to estimate Vz/F

    Time frame: Day 1: Predose and at designated timepoints up to 72 hours post-dose

  23. Amount of Metformin Excreted Unchanged in Urine (Ae)

    Urine samples will be collected at multiple time points to estimate Ae

    Time frame: Day 1: Predose and at designated timepoints up to 48 hours post-dose

  24. Fraction of Metformin Excreted Unchanged in Urine (Fe)

    Urine samples will be collected at multiple time points to estimate Fe

    Time frame: Day 1: Predose and at designated timepoints up to 48 hours post-dose

  25. Renal Clearance of Metformin (CLr)

    Urine samples will be collected at multiple time points to estimate CLr

    Time frame: Day 1: Predose and at designated timepoints up to 48 hours post-dose

  26. Number of Participants Who Experience an Adverse Avent (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who experienced an AE is reported.

    Time frame: Up to approximately 28 days after first dose

  27. Number of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The percentage of participants who discontinued study treatment due to an AE is reported.

    Time frame: Up to approximately 14 days after first dose

07

Study locations

1 site
  • Celerion ( Site 0001)
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2025 to primary completion in Dec 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2025
First posted
Oct 29, 2025
StartActual
Nov 19, 2025
Primary completionActual
Dec 14, 2025
CompletionActual
Dec 29, 2025
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07222098
Responsible party
Sponsor
First posted
Oct 29, 2025
Start date
Nov 19, 2025
Primary completion
Dec 14, 2025
Completion
Dec 29, 2025
Last update
May 6, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rosuvastatin · Metformin

Start the discussion